In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $17.00. Discover outperforming stocks ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $11.00. The company’s shares closed ...

Sutro Biopharma has a 1 year low of $1.70 and a 1 year high of $6.13. The business has a fifty day moving average of $2.98 and a 200-day moving average of $3.50.

Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab ...

STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel ...

Can I get a student discount on my Oakley order? If you are a student, you can get 10% off of your order at Oakley. All you have to do to get this discount is verify your student status via a ...

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category. The deal, which has a top ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

From Potrero Hill, facing The Mission. Photo by Thomas Hunter II.